Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Durvalumab administered IV over 60 minutes at a dose of 1500 mg every 4 weeks

Tremelimumab administered IV over 60 minutes at a dose of 300 mg , twice: at C1D1 and C4D1

21 days after the first immunotherapy treatment 11 fractions of 3 Gy will be administrated to metastatic or primary lesion/s over 2 weeks and one day